IMRX (Immuneering Corporation) stock: $3.68, $238.3M market cap, $166.1M cash, $72.2M EV, $294.3M fully diluted market cap. Next expected readout: Jun-27. Lead program: Atebimetinib (Pancreatic Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive . We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 3 · ActiveModality: small molecule (once-daily oral)
Aliases IMM-1-104
Target MEK (Deep Cyclic Inhibition of MAPK pathway)
Indications
Advanced solid tumors with RAS or RAF mutations(Phase 1)
First-line pancreatic cancer (with modified gemcitabine/nab-paclitaxel)(Phase 3)
Status note Lead product candidate. Phase 3 registrational MAPKeeper 301 in first-line pancreatic cancer (combination with modified gemcitabine/nab-paclitaxel); Phase 1/2a in advanced solid tumors with RAS/RAF mutations. Additional early-stage programs unnamed in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.